Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
The company blasts the US regulator as weeks of uncertainty for its lead drug in Nash end in a complete response letter.
As semaglutide looks set to move into pivotal trials in Nash, Novo Nordisk lays out hopes for longer-term benefits.
Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
Encouraging results from Viking Therapeutics’ lead Nash project have prompted the company to ask how low it can go.
High-profile presentations from the likes of Intercept and Alnylam remain under wraps before Europe’s biggest liver disease conference next month, but the early abstract…
Intercept’s Regenerate trial in Nash, one of the hottest clinical readouts of 2019, is technically a success, but toxicity casts a long shadow.
A stumble for Inventiva’s lanifibranor in a rare fibrotic disease could bode ill for its prospects in Nash, and for those of other PPAR agonists.